HUTCHMED (NASDAQ:HCM) Shares Gap Up – Should You Buy?

Shares of HUTCHMED (China) Limited (NASDAQ:HCM) gapped up before the market opened on Wednesday . The stock had previously closed at $13.72, but opened at $14.36. HUTCHMED shares last traded at $14.60, with a volume of 11,033 shares traded.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Trading Up 7.1 %

The firm’s 50 day moving average is $14.32 and its two-hundred day moving average is $16.95. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81.

Institutional Investors Weigh In On HUTCHMED

Several institutional investors and hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio acquired a new stake in shares of HUTCHMED in the third quarter valued at approximately $35,000. Barclays PLC increased its stake in shares of HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company’s stock valued at $35,000 after purchasing an additional 2,255 shares during the period. Blue Trust Inc. increased its stake in shares of HUTCHMED by 638.2% in the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock valued at $69,000 after purchasing an additional 3,057 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of HUTCHMED by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock valued at $117,000 after purchasing an additional 2,321 shares during the period. Finally, Summit Trail Advisors LLC increased its stake in shares of HUTCHMED by 14.4% in the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock valued at $189,000 after purchasing an additional 1,647 shares during the period. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.